All Updates

All Updates

icon
Filter
Product updates
Owkin unveils AI precision drug pipeline following licensing agreement with Idorsia
AI Drug Discovery
May 23, 2024
Last week:
Partnerships
Geographic expansion
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Industry news
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
AI Drug Discovery

AI Drug Discovery

May 23, 2024

Owkin unveils AI precision drug pipeline following licensing agreement with Idorsia

Product updates

  • Owkin has announced the development of a novel drug pipeline in the areas of oncology and immunology. This comes as part of a global licensing agreement with Idorsia for the development of OKN4395, an advanced inhibitor of prostanoid receptors EP2 and EP4.

  • The drug pipeline is a product of Owkin’s AI engines that integrate cross-modal patient data from over 60 top-notch research centers. Its key characteristics include the use of MOSAIC, the world's most comprehensive spatial multiomics dataset in oncology, and the combination of AI with the specialized knowledge of 110 data scientists.

  • Owkin claims that its precision pipeline, powered by AI, is set on changing how precision health operates by catering specific treatments to distinct patient groups through the analysis of causal biomarkers in patient data.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.